European regulators revoke Amgen's rare disease drug Tavneos over data concerns

European regulators cited flawed and deceptive data as the reason for withdrawing Amgen's Tavneos from the market. The decision, announced last week, was detailed in newly released documents explaining the agency's skepticism. Tavneos was approved for a rare autoimmune condition but faced scrutiny over the integrity of its clinical evidence.